Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Mycol Med ; 31(2): 101113, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-33540367

RESUMO

INTRODUCTION: Cryptococcus gattii species complex is endemic to tropical and subtropical regions and is described as a causative agent of cryptococcosis in immunocompetent individuals. CASE PRESENTATION: We describe the first case of cryptococcosis in a HIV-negative patient from Ivory Coast infected by Cryptococcus gattii sensu stricto VGI. Isolates were recovered from cerebrospinal fluid (CSF) prior to systemic antifungal treatment up to 42 days after detection of the presence of yeasts in the CSF. Eighteen isolates were recovered, genetic diversity and antifungal susceptibility analyses were performed. All the isolates belonged to the Cryptococcus gattii sensu stricto (B;VGI) and were identified as a new sequence type (ST) 553 by Multilocus Sequence Typing (MLST) analyses. Susceptibility testing showed that all the strains had a wild-type phenotype for fluconazole, amphotericin B and flucytosine. Treatment with fluconazole (1200mg/day) was initiated with success. CONCLUSION: This is the first case report of the presence of C. gattii sensu stricto VGI in a HIV-negative ivorian patient and the second report of the presence of species from the C. gattii complex species in this country.


Assuntos
Antifúngicos/farmacologia , Criptococose/diagnóstico , Cryptococcus gattii/efeitos dos fármacos , Cryptococcus gattii/genética , Genótipo , Adulto , Antifúngicos/uso terapêutico , Côte d'Ivoire , Criptococose/líquido cefalorraquidiano , Criptococose/tratamento farmacológico , Criptococose/microbiologia , Cryptococcus gattii/classificação , Cryptococcus gattii/patogenicidade , Feminino , Variação Genética , Infecções por HIV , Humanos , Testes de Sensibilidade Microbiana
2.
J Mycol Med ; 27(1): 72-78, 2017 Mar.
Artigo em Francês | MEDLINE | ID: mdl-28108201

RESUMO

OBJECTIVE: Assessing the use of high-dose fluconazol monotherapy (1200mg or 800mg) in the treatment and prognosis of HIV-associated cryptococcal meningitis in Ivory Coast. PATIENTS AND METHODS: A retrospective study carried out from August 2008 to August 2011 based on patients charts suffering from CM in the Abidjan Tropicals and Infectious Disease Unit. Mortality rate and associated factors were analyzed. RESULTS: Forty-six cases of cryptococcal meningitis (2.5% of hospitalizations) were included. The sex-ratio was of 1.2. The median age was 40.5 [35-47] years. The symptomatology was subacute (93.5%). The main clinical symptoms were syndrome of pure meningeal irritation (65%), fever (100%); 35% of patients had encephalomeningits. Twenty-one (45.7%) was ART-naïve patients. Fluconazole 1200mg was prescribed to 29 (63%) patients. Therapeutic lumbar punctures were performed in 42 (91.3) patients. The mortality rate was 50%. Significant predictors of mortality were encephalomeningitis and therapeutic lumbar puncture. CONCLUSION: Cryptococcal meningitis associated mortality remains high despite the use of high-dose fluconazole monotherapy. Therapeutic lumbar punctures help to improving the prognosis.


Assuntos
Antifúngicos/administração & dosagem , Fluconazol/administração & dosagem , Meningite Criptocócica/tratamento farmacológico , Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Infecções Oportunistas Relacionadas com a AIDS/epidemiologia , Adulto , Côte d'Ivoire/epidemiologia , Relação Dose-Resposta a Droga , Feminino , HIV , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Humanos , Masculino , Meningite Criptocócica/epidemiologia , Pessoa de Meia-Idade , Estudos Retrospectivos
3.
Artigo em Francês | AIM (África) | ID: biblio-1271832

RESUMO

Le dépistage systématique du cancer du col de l'utérus chez les femmes infectées par le Vih est recommandé par l'oMS et effectif en Côte d'ivoire depuis 2009. l'objectif était de partager l'expérience de cette pratique en routine chez les femmes infectées par le Vih suivies dans un service d'infectiologie à abidjan. il s'est agit d'une étude rétrospective des dossiers de patientes âgées de 25 à 65 ans, infectées par le Vih, suivies au SMiT entre 2010 et 2014. la technique d'inspection visuelle à l'acide acétique (iVa) a été utilisée pour le dépistage. les données socio-démographiques, cliniques et thérapeutiques recueillies ont été analysées à l'aide des logiciels excel 2007 et STaTa version 13.0. le test statistique utilisé pour comparer les pourcentages était le khi deux ou le test exact de Fischer. les différences observées ont été considérées comme significatives en dessous de 5 %. la variable d'intérêt était la réalisation d'au moins un test iVa en routine. Selon le résultat du test iVa, le profil clinique et immunovirologique des patientes a été analysé en précisant la conduite à tenir selon l'indication. enfin la poursuite du dépistage a été notifiée dans le temps spécifiquement chez les femmes négatives au test initial. entre 2010 et 2014, 4 368 femmes infectées par le Vih étaient éligibles au dépistage du cancer du col. Parmi elles, 301 femmes (6,9 %) en ont bénéficié. l'âge médian était de 38 ans [25 - 58 ans]. la médiane des Cd4 au bilan de suivi lors du test iVa était de 291 cellules/mm3 [2 ­ 1 876 cellules/mm3]. le dépistage était positif pour 24 femmes (8 %) et selon les indications, 6 femmes étaient éligibles à la cryothérapie (26 %), 6 à la résection à l'anse diathermique (26 %) et 10 à la réalisation d'un frottis cervico-vaginal, pour une suspicion de cancer invasif (44 %). les patientes positives au test iVa étaient relativement plus jeune (35 vs 38 ans ; p = 0,03). aucun contrôle ultérieur n'a été effectué chez 90 % (n = 249) de celles qui ont eu un test iVa négatif au premier dépistage. le dépistage systématique est peu réalisé en routine au cours du suivi des femmes Vih. les défis opérationnels doivent être relevés pour une optimisation des soins en afrique

4.
Med Mal Infect ; 45(8): 324-7, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26344815

RESUMO

OBJECTIVE: We described the use of antiretroviral drugs to prevent HIV transmission among children and adolescents victims of rape in Abidjan (Ivory Coast). MATERIALS AND METHOD: We conducted a retrospective and descriptive study on children (0-9 years) and adolescents (10-19 years) victims of rape between 2000 and 2013. We analyzed the patients' socio-demographic characteristics and the modality of the chemoprophylaxis. RESULTS: We included 10 children and 89 adolescents in the study. The median age was 16 years old (3-19 years). The median time to consultation was 23.5 hours (5-152 hours). The antiretroviral chemoprophylaxis was administered to 92 patients (93%). No HIV and HBV seroconversion was observed after a 3-month follow-up. CONCLUSION: A better management of rape victims is required in Abidjan.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/prevenção & controle , Estupro , Adolescente , Fármacos Anti-HIV/administração & dosagem , Criança , Pré-Escolar , Côte d'Ivoire , Feminino , Seguimentos , Anticorpos Anti-HIV/sangue , Infecções por HIV/transmissão , Soropositividade para HIV , Necessidades e Demandas de Serviços de Saúde , Hepatite B/transmissão , Anticorpos Anti-Hepatite B/sangue , Humanos , Masculino , Estudos Retrospectivos , Soroconversão , Fatores Socioeconômicos , Adulto Jovem
5.
Rev. int. sci. méd. (Abidj.) ; 15(3): 228-231, 2013.
Artigo em Francês | AIM (África) | ID: biblio-1269132

RESUMO

Introduction : L'efficacite des traitements antiretroviraux (ARV) peut entrainer des phenomenes inflammatoires de restauration immune (IRIS) ou auto-immuns paradoxaux sous forme de pathologies infectieuses telles que la tuberculose ou la cryptococcose. Observation: Nous rapportons un cas inhabituel de syndrome inflammatoire de restauration immune sous la forme d'une cryptococcose disseminee avec des atteintes meningees et cerebrales chez un patient de 56 ans infecte par le VIH-1 qui a consulte pour un trouble de la vigilance; des crises convulsives et une hemiparesie droite. Le patient avait repondu favorablement a un traitement antifongique par fluconazole institue pour une meningite a cryptocoque un mois avant son admission. Un traitement ARV avait ete initie une dizaine de jours apres le traitement anticryptococcique. Apres deux semaines effective de traitement ARV; le tableau clinique etait marque par la reapparition des symptomes neuro-meninges et leur aggravation. L'examen a l'encre de chine du liquide cephalorachidien (LCR) mettait en evidence des spores de Cryptococcus neoformans. La recherche de l'antigene cryptococcique etait positive et la culture sur milieu de Sabouraud montrait des colonies de Cryptococcus Neoformans. L'IRM cerebrale notait de multiples lesions d'abces. L'evolution a ete fatale apres 11 jours de traitement. Conclusion : Le cryptococcome associe a l'IRIS est peu decrit en Afrique. La generalisation actuelle des ARV sur ce continent pourrait entrainer une recrudescence de cette manifestation


Assuntos
Síndrome Inflamatória da Reconstituição Imune , Meningite Criptocócica
6.
Med Mal Infect ; 40(10): 574-81, 2010 Oct.
Artigo em Francês | MEDLINE | ID: mdl-20554137

RESUMO

OBJECTIVE: The aim of this study was to assess the tolerability and adherence to all non-occupational post-exposure prophylaxis (PEP) for cases of HIV exposure in Abidjan. METHOD: We retrospectively studied all post-exposure prophylaxis for non-occupational exposures to HIV prescribed from January 1st, 2000 to December 31st, 2007 in the Abidjan infectious diseases department. We analyzed the types of exposure, socio-demographic characteristics of patients, antiretroviral therapy regimens, adherence and tolerability, duration of the treatment, and post-exposure follow-up. RESULTS: Over these eight years, we managed 128 consultations for non-professional exposures to HIV (50 male [39%], 78 female patients [61%]), average age 24.8 years (four-54 years). The most frequent exposures were due to rape (n=74), condom rupture (n=29), and occasional unprotected sex (n=21). The average delay before consultation was 20.8 hours. The antiretroviral chemoprophylaxis included a protease inhibitor in 93% of the cases; 80.5% of patients completed 28 days of chemoprophylaxis, while 8.6% interrupted the treatment, and 10.9% were lost to follow-up. The most frequent adverse effects were gastrointestinal, reported by 79 patients (61.7%). Only 34 patients (26.6%) returned for clinical and biological post-exposure follow-up with HIV control at third month, without documented seroconversion. CONCLUSION: Cases of sexual exposure to HIV are the main indication for post-exposure prophylaxis in Abidjan, except for occupational exposure to blood. However, post-exposure prophylaxis should be available in the units of primary care, such as emergencies departments.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/prevenção & controle , Profilaxia Pós-Exposição , Adolescente , Adulto , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/efeitos adversos , Mordeduras Humanas , Criança , Pré-Escolar , Preservativos , Côte d'Ivoire , Falha de Equipamento , Feminino , Gastroenteropatias/induzido quimicamente , Infecções por HIV/transmissão , Inibidores da Protease de HIV/administração & dosagem , Inibidores da Protease de HIV/efeitos adversos , Inibidores da Protease de HIV/uso terapêutico , Soropositividade para HIV , Humanos , Masculino , Pessoa de Meia-Idade , Ferimentos Penetrantes Produzidos por Agulha , Cooperação do Paciente , Profilaxia Pós-Exposição/estatística & dados numéricos , Estupro , Estudos Retrospectivos , Resultado do Tratamento , Sexo sem Proteção , Adulto Jovem
7.
Mali Med ; 25(1): 37-41, 2010.
Artigo em Francês | MEDLINE | ID: mdl-21441082

RESUMO

OBJECTIVE: To evaluate the efficacy of antiretroviral treatment in elderly people followed at the Unit for Infectious and Tropical Diseases at the University Hospital in Abidjan. MATERIAL AND METHODS: We performed a retrospective descriptive study of the files of people aged at least 60 years, infected by HIV who were treated and followed-up in the Unit between 1 January 1999 and 31 December 2006. We analysed sociodemographic (age, sex), clinical (weight, Karnofsky scale, CDC, opportunistic infections), biological (HIV, CD4, haemogram, glycaemia, creatininaemia, transaminasaemia) and therapeutic (antiretroviral regimens, evolution, side-effects) parameters. The efficacy of treatment was evaluated as the percentage of patients with < 200 CD4/ml, and its safety was based on deleterious effects. RESULTS: We studied 62 patients (44 men, 18 women), of whom 13 had been treated (21%), 46 had not been treated (74.2%) and 48 (77.4%) were undergoing chemoprophy-laxis with cotrimoxazole. Most were infected with HIV1 (93.6%), 3.2% with HIV2 and 3.2% with both HIV1 and HIV2. The majority (93.3%) was symptomatic, and 67.8% had AIDS. During 34 months of follow-up, 48 patients (77.4%) received first-line treatment, 13 (21%) received second-line and only one patient (1.6%) had third-line treatment. The percentage of patients with more than 200 CD4/ml increased from 20% at baseline to 36% at 6 months and 39% at 12 months. The main clinical side-effect was peripheral neuropathy (30.5%), and the main biological effect was hypertransaminasaemia > 2N (32.3%). The median rate of loss to follow-up was 17.7%, and two patients (3.2%) died. CONCLUSION: Antiretroviral treatment is effective in the elderly, with few biological disorders. A prospective study of a larger sample would elucidate the differences from younger people in the efficacy of such treatment.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , HIV-1 , HIV-2 , Infecções Oportunistas Relacionadas com a AIDS/epidemiologia , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/epidemiologia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Fármacos Anti-HIV/efeitos adversos , Contagem de Linfócito CD4 , Doença Hepática Induzida por Substâncias e Drogas/epidemiologia , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Côte d'Ivoire/epidemiologia , Bases de Dados Factuais , Quimioterapia Combinada , Feminino , Seguimentos , Gastroenteropatias/induzido quimicamente , Gastroenteropatias/epidemiologia , Infecções por HIV/epidemiologia , Hospitais Universitários/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Doenças do Sistema Nervoso Periférico/induzido quimicamente , Doenças do Sistema Nervoso Periférico/epidemiologia , Estudos Retrospectivos
8.
Mali méd. (En ligne) ; 25(1): 37-41, 2010.
Artigo em Francês | AIM (África) | ID: biblio-1265619

RESUMO

Objectif : Evaluer l'efficacite du traitement antiretroviral chez les sujets ages suivis dans le service des Maladies Infectieuses et Tropicales a Abidjan. Materiel et Methodes : Il s'agit d'une etude retrospective; descriptive et portant sur l'analyse des dossiers de sujets ages d'au moins 60 ans; infectes par le VIH; traites et suivis dans le service des Maladies Infectieuses et Tropicales entre le 1er janvier 1999 et le 31 decembre 2006. L'analyse a porte sur les parametres sociodemographiques (age; sexe); cliniques ARV; (poids; score Karnofsky; stade CDC; affections opportunistes); biologiques (type de VIH; CD4; hemogramme; glycemie; creatininemie; transaminasemie) et therapeutiques (regimesA RV; evolution; effets secondaires). L'efficacite du traitement etait basee sur le pourcentage de patients ayant un taux de CD4 200 / ml et la tolerance basee sur les effets deleteres. Resultats : L'etude a concerne 62 sujets ages (44 hommes / 18 femmes); dont 13 pretraites (21); 46 naifs (74;20) et 48 (77;42) sous chimioprophylaxie au cotrimoxazole. La majorite de l'effectif etait infectee par le VIH1 (93;60) contre 3;20pour le VIH2 et 3;20pour le VIH 1+2. Ils etaient symptomatiques a 93;3avec 67;8au stade SIDA. En trente quatre mois de suivi; 48 patients ont recu un regime de premiere ligne (77;4) ; 13 de deuxieme ligne (20;96) et un seul patient avait un regime de troisieme ligne (1;6). L'analyse des resultats a montre que le pourcentage des patients ayant un taux des CD4 200 etait croissant; passant de 20a M0 a 36a M6 puis 39a M12. Quant aux effets secondaires; ils etaient cliniquement domines par les neuropathies peripheriques (30;5) et biologiquement par l'hypertransaminasemie 2N (32;3). Le taux median de perdus de vue etait de 17;7; et 2 patients (3;22) sont decedes. Conclusion : Le traitement ARV est efficace chez les personnes agees avec peu d'anomalies biologiques; aussi; une etude prospective sur un plus grand echantillonnage permettrait-elle de mieux percevoir les differences avec le sujet jeune


Assuntos
Síndrome da Imunodeficiência Adquirida , Idoso , Terapia Antirretroviral de Alta Atividade , Infecções por HIV
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...